SEC Form EFFECT filed by BioHarvest Sciences Inc.
$BHST
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 8, 2025 9:00 A.M. |
| Form: | F-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 8, 2025 9:00 A.M. |
| Form: | F-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/5/2025 | $15.00 | Buy | Craig Hallum |
| 12/18/2024 | $12.00 | Buy | Maxim Group |
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 7, 2026) - BioHarvest Sciences Inc., (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today issued a letter to shareholder partners from Chief Executive Officer, Ilan Sobel.Dear Fellow Shareholders,2025 marked an important milestone for BioHarvest Sciences: our first full year as a NASDAQ-listed company, and we enter 2026 with an annualized revenue run rate exceeding US$36 million and gross margins above 60%. It was a year of execution, validation, and capability -building across both of our complementary businesses — D2C Products and
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - December 18, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ platform, today announced that it has been awarded a $1.6 million grant from the Israeli Innovation Authority (IIA). The grant was approved under the IIA's Bio-Convergence program, which supports technologies at the intersection of biology, engineering, data science, and artificial intelligence.The non-dilutive funding will support the development of new innovative capabilities for BioHarvest's second-generation Botanical Synthesis™ process, enabling t
First Hydration Formula Powered by VINIA's Blood Flow Technology Enters the $13 Billion U.S. Electrolyte MarketVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - December 3, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the U.S. launch of VINIA Blood Flow Hydration™, the first hydration solution powered by the blood flow benefits of VINIA's Piceid resveratrol to enter the $13 Billion US Electrolytes Drink Market*.Better Hydration Starts with Better Blood FlowFollowing overwhelmingly positive early-adopter interest, VINIA Blood Flow Hydration™ is n
6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
AW - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
POS AM - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
Craig Hallum initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $15.00
Maxim Group initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $12.00
Strong VINIA Momentum and New CDMO Win Delivers 39% Year-Over-Year GrowthCompany Fortifies Balance Sheet with Recent $19.9 Million Instiutional Equity Raise Following $14.7 Million Strengthening of Balance Sheet via Accelerated Warrant Exercises and Debt-to-Equity Conversions in SeptemberVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 13, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the third quarter ended September 30, 2025.Third Quarter 2025 Operational HighlightsAll figu
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 4, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 13, 2025.Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on Thursday, November 13, 2025 to discuss the Company's third quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate,
Robust 41% Year-Over-Year Revenue Growth, Driven by Strong Core Capsule and New Product SalesRehovot, Israel--(Newsfile Corp. - August 11, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the second quarter ended June 30, 2025.Second Quarter 2025 HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the second quarter of 2025 increased 41% year-over-year to $8.5 million, in line with management guidance, with gross margins of 60% expanding by 800 basis points y
Veteran Technology Leader Brings 25+ Years of Financial and Capital Markets Experience to the BoardVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 22, 2025) - BioHarvest Sciences Inc., (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest. The appointment is effective immediately."We are very pleased to announce the addition of Mr. Malka to the BioHarvest Board of Directors," said Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division